(19)
(11) EP 2 561 902 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
03.04.2013 Bulletin 2013/14

(88) Date of publication A3:
27.02.2013 Bulletin 2013/09

(43) Date of publication:
27.02.2013 Bulletin 2013/09

(21) Application number: 12180426.4

(22) Date of filing: 05.10.2005
(51) International Patent Classification (IPC): 
A61N 1/08(2006.01)
A61N 1/32(2006.01)
 A61N 1/05(2006.01)
A61B 18/14(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 13.05.2005 US 129765
05.10.2004 US 616254 P
02.11.2004 US 624793 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11192511.1 / 2457614
10190952.1 / 2329859
05806045.0 / 1802370

(71) Applicant: Medtronic Ardian Luxembourg S.à.r.l.
2124 Luxembourg (LU)

(72) Inventors:
  • Deem, Mark
    Mountain View, CA California (US)
  • Gifford, Hanson
    Woodside, CA California (US)
  • Zarins, Denise
    Saratoga, CA California 95070 (US)
  • Sutton, Douglas
    Pacifica, CA California (US)
  • Thai, Erik
    San Jose, CA California (US)
  • Gelfand, Mark
    New York, NY New York 10001 (US)
  • Levin, Howard R.
    Teaneck, NJ New Jersey 07666 (US)

(74) Representative: Zimmermann & Partner 
Josephspitalstr. 15
80331 München
80331 München (DE)

 
Remarks:
This application was filed on 14-08-2012 as a divisional application to the application mentioned under INID code 62.
Remarks:
Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).
 


(54) Apparatus for renal neuromodulation


(57) Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.